National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Veletri® is indicated for the treatment of pulmonary arterial hypertension (PAH) (idiopathic or heritable PAH and PAH associated with connective tissue diseases) in patients with WHO FC III–IV symptoms to improve exercise capacity.

 Rapid Review

Commenced Completed Outcome
13/12/2016 06/02/2017 Full Pharmacoeconomic Evaluation Not Recommended